Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.

Madhavan M. et al, (2022), EBioMedicine

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Padron-Regalado E. et al, (2022), Sci Rep, 12

Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies.

Ng WM. et al, (2022), Cell Host Microbe

Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.

Jenkin D. et al, (2022), Lancet Microbe

Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies

Ng W. et al, (2022)

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Joe CCD. et al, (2022), Biotechnol Bioeng, 119, 48 - 58

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Sci Rep, 11

Stability of chimpanzee adenovirus vectored vaccines (Chadox1 and chadox2) in liquid and lyophilised formulations

Berg A. et al, (2021), Vaccines, 9

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P. et al, (2021), Sci Rep, 11

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.

Feng S. et al, (2021), Nat Med

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Minassian AM. et al, (2021), Med (N Y), 2, 701 - 719.e19

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Barrett JR. et al, (2021), Nature medicine

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nature medicine

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial.

LAMBE T. et al, (2020), Nature Medicine

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Barrett JR. et al, (2020), Nat Med

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey M. et al, (2020), Lancet

Include forthcoming?